Mostrar el registro sencillo

dc.contributor.authorRosa Garrido, Manuel 
dc.contributor.authorCeballos Castillo, Laura
dc.contributor.authorAlonso Lecue, Pilar
dc.contributor.authorAbraira Meriel, Cristina
dc.contributor.authorDelgado Villar, María Dolores 
dc.contributor.authorGandarillas Solinís, Alberto 
dc.contributor.otherUniversidad de Cantabriaes_ES
dc.date.accessioned2016-01-27T11:19:25Z
dc.date.available2016-01-27T11:19:25Z
dc.date.issued2012-06-19
dc.identifier.issn1932-6203
dc.identifier.urihttp://hdl.handle.net/10902/7971
dc.description.abstractCTCF is a ubiquitous epigenetic regulator that has been proposed as a master keeper of chromatin organisation. CTCF-like, or BORIS, is thought to antagonise CTCF and has been found in normal testis, ovary and a large variety of tumour cells. The cellular function of BORIS remains intriguing although it might be involved in developmental reprogramming of gene expression patterns. We here unravel the expression of CTCF and BORIS proteins throughout human epidermis. While CTCF is widely distributed within the nucleus, BORIS is confined to the nucleolus and other euchromatin domains. Nascent RNA experiments in primary keratinocytes revealed that endogenous BORIS is present in active transcription sites. Interestingly, BORIS also localises to interphase centrosomes suggesting a role in the cell cycle. Blocking the cell cycle at S phase or mitosis, or causing DNA damage, produced a striking accumulation of BORIS. Consistently, ectopic expression of wild type or GFP- BORIS provoked a higher rate of S phase cells as well as genomic instability by mitosis failure. Furthermore, downregulation of endogenous BORIS by specific shRNAs inhibited both RNA transcription and cell cycle progression. The results altogether suggest a role for BORIS in coordinating S phase events with mitosis.es_ES
dc.description.sponsorshipThis study was supported by the Instituto de Salud Carlos III-Fondo de Investigaciones Sanitarias (ISCIII-FIS; National Grants, Spain): FIS-PI08/0829, FIS-PI11/00397 and Red Temática de Investigación Cooperativa en Cáncer-RTICC-RD06/0020/017 (MDD); FIS-PI08/0890, FIS-PI11/02070 and Programa Regiones Emergentes-EMER (AG); by the Société Française de Dermatologie (SFD, France; AG); and by a co-operative grant from Universidad de Cantabria-Fundación Marqués de Valdecilla-IFIMAV (Cantabria, Spain; Javier León-AG). MRG was recipient of a fellowship from University of Cantabria. Both MRG and PA were also funded by Fundación Leonardo Torres Quevedo and Fundación Marqués de Valdecilla-IFIMAV. AG is ‘on leave’ at the Institut National de la Santé et de la Recherche Médicale (INSERM, France). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
dc.format.extent15 p.es_ES
dc.language.isoenges_ES
dc.publisherPublic Library of Sciencees_ES
dc.rightsAttribution 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.sourcePLoS One, 2012, 7(6), e39371es_ES
dc.titleA cell cycle role for the epigenetic factor CTCF-L/BORISes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.accessRightsopenAccesses_ES
dc.identifier.DOI10.1371/journal.pone.0039371
dc.type.versionpublishedVersiones_ES


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo

Attribution 4.0 InternationalExcepto si se señala otra cosa, la licencia del ítem se describe como Attribution 4.0 International